The Relative Strength (RS) Rating for Disc Medicine climbed into a new percentile Thursday, as it got a lift from 70 to 78.
This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating of above 80 as they begin their largest price moves. See if Disc Medicine can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Disc Medicine is not currently near a potential buying area. See if the stock goes on to form a chart pattern that could spark a new run.
The company showed 0% EPS growth last quarter, while sales growth came in at 0%.
The company earns the No. 185 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
